Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension

Physiological Research

Volumn 62, Issue SUPPL 1, 2013, Pages

  Repova Bednarova K ^a   Aziriova S ^a   Hrenak J ^a   Krajcirovicova K ^a   Adamcova M ^c   Paulis, L ^a   Simko F ^a,b,d  

^a Bratislava   (Slovakia)

^b INSTITUTE OF EXPERIMENTAL ENDOCRINOLOGY   (Slovakia)

^c CHARLES UNIVERSITY   (Czech Republic)

^d Centrum of Excellence NOREG   (Slovakia)

Author keywords

Captopril; Collagen I and III; Continuous light; Fibrosis; Hypertension; Melatonin

Indexed keywords

ANTIFIBRINOLYTIC AGENT; ANTIHYPERTENSIVE AGENT; CAPTOPRIL; FIBRILLAR COLLAGEN; MELATONIN;

ANIMAL; AORTA; ARTERIAL STIFFNESS; ARTICLE; DRUG EFFECT; HYPERTENSION; LIGHT; MALE; METABOLISM; PATHOPHYSIOLOGY; PHOTOSTIMULATION; RAT; WISTAR RAT;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; ANTIHYPERTENSIVE AGENTS; AORTA; CAPTOPRIL; FIBRILLAR COLLAGENS; HYPERTENSION; LIGHT; MALE; MELATONIN; PHOTIC STIMULATION; RATS; RATS, WISTAR; VASCULAR STIFFNESS;

EID: 84891642981     PISSN: 08628408     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. ARANGINO S, CAGNACCI A, ANGIOLUCCI M, VACCA AM, LONGU G, VOLPE A, MELIS GB: Effects of melatonin on vascular reactivity, catecholamine levels, and blood pressure in healthy men. Am J Cardiol 83: 1417-1419, 1999.
2. DOBRIN PB, MRKVICKA R: Failure of elastin or collagen as possible critical connective tissue alterations underlying aneurysmal dilatation. Cardiovasc Surg 2: 484-488, 1994.
3. DOMINGUEZ-RODRIGUEZ A, ABREU-GONZALEZ P, SANCHEZ-SANCHEZ JJ, KASKI JC, REITER RJ: Melatonin and circadian biology in human cardiovascular disease. J Pineal Res 49: 14-22, 2010.
4. GROSSMAN E, LAUDON M, YALCIN R, ZENGIL H, PELEG E, SHARABI Y, KAMARI Y, SHEN-ORR Z, ZISAPEL N: Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 119: 898-902, 2006.
5. GROSSMAN E, LAUDON M, ZISAPEL N: Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 7: 577-584, 2011.
6. IVANISEVIC-MILOVANOVIC OK, DEMAJO M, KARAKASEVIC A, PANTIC V: The effect of constant light on the concentration of catecholamines of the hypothalamus and adrenal glands, circulatory hadrenocorticotropin hormone and progesterone. J Endocrinol Invest 18: 378-383, 1995.
7. JONAS M, GARFINKEL D, ZISAPEL N, LAUDON M, GROSSMAN E: Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. Blood Press 12: 19-24, 2003.
8. LI HL, KANG YM, YU L, XU HY, ZHAO H: Melatonin reduces blood pressure in rats with stress-induced hypertension via GABAA receptors. Clin Exp Pharmacol Physiol 36: 436-440, 2009.
9. MILOSEVIC V, TRIFUNOVIC S, SEKULIC M, SOSIC-JURJEVIC B, FILIPOVIC B, NEGIC N, NESTOROVIC N, MANOJLOVIC STOJANOSKI M, STARCEVIC V: Chronic exposure to constant light affects morphology and secretion of adrenal zona fasciculata cells in female rats. Gen Physiol Biophys 24: 299-309, 2005.
10. PAULIS L, SIMKO F: Blood pressure modulation and cardiovascular protection by melatonin: potential mechanisms behind. Physiol Res 56: 671-684, 2007.
11. PAULIS L, PECHANOVA O, ZICHA J, KRAJCIROVICOVA K, BARTA A, PELOUCH V, ADAMCOVA M, SIMKO F: Melatonin prevents fibrosis but not hypertrophy development in the left ventricle of NG-nitro-Larginine- methyl ester hypertensive rats. J Hypertens Suppl 27: S11-S16, 2009.
12. PAULIS L, PECHANOVA O, ZICHA J, BARTA A, GARDLIK R, CELEC P, KUNES J, SIMKO F: Melatonin interactions with blood pressure and vascular function during L-NAME-induced hypertension. J Pineal Res 48: 102-108, 2010a.
13. PAULIS L, PECHANOVA O, ZICHA J, LISKOVA S, CELEC P, MULLEROVA M, KOLLAR J, BEHULIAK M, KUNES J, ADAMCOVA M, SIMKO F: Melatonin improves the restoration of endothelium-derived constricting factor signalling and inner diameter in the rat femoral artery after cessation of L-NAME treatment. J Hypertens 28 (Suppl 1): S19-S24, 2010b.
14. PAULIS L, SIMKO F, LAUDON M: Cardiovascular effects of melatonin receptor agonists. Expert Opin Investig Drugs 21: 1661-1678, 2012.
15. PECHANOVA O, ZICHA J, PAULIS L, ZENEBE W, DOBESOVA Z, KOJSOVA S, JENDEKOVA L, SLADKOVA M, DOVINOVA I, SIMKO F, KUNES J: The effect of N-acetylcysteine and melatonin in adult spontaneously hypertensive rats with established hypertension. Eur J Pharmacol 561: 129-136, 2007.
16. PELOUCH V, MILEROVA M, OSTADAL B, HUCIN B, SAMANEK M: Differences between atrial and ventricular protein profiling in children with congenital heart disease. Mol Cell Biochem 147: 43-49, 1995.
17. RECHCINSKI T, TRZOS E, WIERZBOWSKA-DRABIK K, KRZEMINSKA-PAKULA M, KURPESA M: Melatonin for nondippers with coronary artery disease: assessment of blood pressure profile and heart rate variability. Hypertens Res 33: 56-61, 2010.
18. REITER RJ, TAN DX, TERRON MP, FLORES LJ, CZARNOCKI Z: Melatonin and its metabolites: new findings regarding their production and their radical scavenging actions. Acta Biochim Pol 54: 1-9, 2007.
19. REITER RJ, TAN DX, FUENTES-BROTO L: Melatonin: a multitasking molecule. Prog Brain Res 181: 127-151, 2010.
20. REZZANI R, PORTERI E, DE CIUCEIS C, BONOMINI F, RODELLA LF, PAIARDI S, BOARI GE, PLATTO C, PILU A, AVANZI D, RIZZONI D, AGABITI ROSEI E: Effects of melatonin and Pycnogenol on small artery structure and function in spontaneously hypertensive rats. Hypertension 55: 1373-1380, 2010.
21. SCHEER FA, VAN MONTFRANS GA, VAN SOMEREN EJ, MAIRUHU G, BUIJS RM: Daily nighttime melatonin reduces blood pressure in male patients with essential hypertension. Hypertension 43: 192-197, 2004.
22. SCHIFFRIN EL: Vascular remodeling in hypertension: mechanisms and treatment. Hypertension 59: 367-374, 2012.
23. SIMKO F, PAULIS L: Melatonin as a potential antihypertensive treatment. J Pineal Res 42: 319-322, 2007.
24. SIMKO F, PAULIS L. Hypertensive heart disease: bone marrow as a significant player in pathologic remodelling? J Hypertens 30: 1702-1705, 2012.
25. SIMKO F, PAULIS L: Antifibrotic effect of melatonin - perspective protection in hypertensive heart disease. Int J Cardiol 168: 2876-2877, 2013.
26. SIMKO F, PECHANOVA O: Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. J Pineal Res 47: 127-133, 2009.
27. SIMKO F, SIMKO J, FABRYOVA M: ACE-inhibition and angiotensin II receptor blockers in chronic heart failure: pathophysiological consideration of the unresolved battle. Cardiovasc Drugs Ther 17: 287-290, 2003.
28. SIMKO F, MATUSKOVA J, LUPTAK I, KRAJCIROVICOVA K, KUCHARSKA J, GVOZDJAKOVA A, BABAL P, PECHANOVA O: Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 74: 1211-1224, 2004.
29. SIMKO F, PECHANOVA O, PELOUCH V, KRAJCIROVICOVA K, MULLEROVA M, BEDNAROVA K, ADAMCOVA M, PAULIS L: Effect of melatonin, captopril, spironolactone and simvastatin on blood pressure and left ventricular remodelling in spontaneously hypertensive rats. J Hypertens Suppl 27: S5-S10, 2009.
30. SIMKO F, PECHANOVA O, PELOUCH V, KRAJCIROVICOVA K, CELEC P, PALFFY R, BEDNAROVA K, VRANKOVA S, ADAMCOVA M, PAULIS L: Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril. J Hypertens 28 (Suppl 1): S13-S18, 2010.
31. SIMKO F, REITER RJ, PECHANOVA O, PAULIS L: Experimental models of melatonin-deficient hypertension. Front Biosci-Landmark 18: 616-625, 2013.
32. TENGATTINI S, REITER RJ, TAN DX, TERRON MP, RODELLA LF, REZZANI R: Cardiovascular diseases: protective effects of melatonin. J Pineal Res 44: 16-25, 2008.
33. WEBER KT: Cardiac interstitium in health and disease: the fibrillar collagen network. J Am Coll Cardiol 13: 1637-1652, 1989.
34. XIA CM, SHAO CH, XIN L, WANG YR, DING CN, WANG J, SHEN LL, LI L, CAO YX, ZHU DN: Effects of melatonin on blood pressure in stress-induced hypertension in rats. Clin Exp Pharmacol Physiol 35: 1258-1264, 2008.
35. ZEMAN M, DULKOVA K, BADA V, HERICHOVA I: Plasma melatonin concentrations in hypertensive patients with athe dipping and non-dipping blood pressure profile. Life Sci 76: 1795-1803, 2005.